Pas­cal So­ri­ot says 2020 ap­proval still pos­si­ble for As­traZeneca's Covid-19 vac­cine as the world awaits the safe­ty board­'s de­ci­sion

Mod­er­na was the first com­pa­ny to put a vac­cine can­di­date in­to hu­mans, but for much of the pan­dem­ic it was As­traZeneca and their aca­d­e­m­ic part­ners at Ox­ford Uni­ver­si­ty putting out the most ag­gres­sive time­lines. They signed deals with the UK promis­ing to sup­ply dos­es as ear­ly as Sep­tem­ber and Sarah Gilbert, the vac­cine’s aca­d­e­m­ic ar­chi­tect, talked, al­beit cau­tious­ly, about get­ting ef­fi­ca­cy da­ta by that time.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA